ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Tislelizumab augment the efficacy of CD19/22 dual-targeted chimeric antigen receptor T cell in advanced stage relapsed or refractory B-cell non-Hodgkin lymphoma

Zhang, Ying; Geng, Hongzhi; Zeng, Liangyu; Li, Jiaqi; Yang, Qin; Jia, Sixun; Zong, Xiangping; Cai, Wenzhi; Liu, Shuangzhu; Lu, Yutong; Yu, Lei; Li, Caixia*; Wu, Depei*苏州大学; 1
Hematological Oncology2023-9-30DOI: 10.1002/hon.3227
6阅读
引用收藏
分享

摘要

Dual-targeted chimeric antigen receptor T (CAR-T) cell is an important strategy to improve the efficacy of CD19 CAR-T cell against refractory or relapsed B cell non-Hodgkin lymphoma (R/R B-NHL). However, durable responses are not achieved in most patients, in part owing CAR-T cell exhaustion caused by PD-1/PD-L1 pathway. We conducted a prospective, single-arm study of dual-targeted CD19/22 CAR-T cell combined with anti-PD-1 antibody, tislelizumab, in R/R B-NHL (NCT04539444). Tislelizumab was administrated on +1 day after patients received infusion of CD19/22 CAR-T cell. Responses, survival and safety were evaluated. From 1 August 2020 to 30 March 2023, 16 patients were enrolled. The median follow-up time is 16.0 (range: 5.0-32.0 months) months. Overall response was achieved in 14 of 16 (87.5%) patients, and the complete response (CR) was achieved in 11 of 16 (68.8%) patients. The 1-year progression-free survival and overall survival rates were 68.8% and 81.3%, respectively. Of the 14 patients responded, 9 patients maintained their response until the end of follow-up. Among the 15 out of 16 (93.8%) patients who had extranodal involvement, 14 (93.3%) patients achieved overall response rate with 11 (73.3%) patients achieving CR. Eight (50%) patients experienced cytokine release syndrome. No neurologic adverse events were reported. Gene Ontology-Biological Process enrichment analysis showed that immune response-related signaling pathways were enriched in CR patients. Our results suggest that CD19/22 CAR-T cell combined with tislelizumab elicit a safe and durable response in R/R B-NHL and may improve the prognosis of those patients.

学科与关键词

关键词
anti-PD-1 antibodyCD19/CD22 chimeric antigen receptor T cellrefractory or relapsed B cell non-Hodgkin lymphomatislelizumab
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
Hematological Oncology
发表日期
2023-09-30
DOI
10.1002/hon.3227
语言
ENGLISH
成果收录
SCIE
资助标注
Priority Academic Program Development of Jiangsu Higher Education Institutions Suzhou Science and Technology Program Project [SLT201911]; National Natural Science Foundation of China [82020108003]; National Key R & D Program of China [2022YFC2502700]; Translational Research [NCRCH, 2020WSC03]

作者

  • Z

    Zhang, Ying (第一作者)

    soochow univ · 1

  • G

    Geng, Hongzhi

    soochow univ · 1

查看全部 13 位作者收起作者
  • Z

    Zeng, Liangyu

    soochow univ · 1

  • L

    Li, Jiaqi

    soochow univ · 1

  • Y

    Yang, Qin

    soochow univ · 1

  • J

    Jia, Sixun

    soochow univ · 1

  • Z

    Zong, Xiangping

    soochow univ · 1

  • C

    Cai, Wenzhi

    soochow univ · 1

  • L

    Liu, Shuangzhu

    soochow univ · 1

  • L

    Lu, Yutong

    soochow univ · 1

  • Y

    Yu, Lei

    new

  • L

    Li, Caixia (通讯)

    1 · soochow univ

  • W

    Wu, Depei (通讯)

    1 · soochow univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417